Can-Fite BioPharma Ltd. (CANF)
USD 1.33
(-6.34%)
USD 1.33
(-6.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.93 Million USD | -18.18% |
| 2022 | 10.9 Million USD | -20.37% |
| 2021 | 13.69 Million USD | -8.1% |
| 2020 | 14.9 Million USD | 6.15% |
| 2019 | 14.03 Million USD | 52.04% |
| 2018 | 9.23 Million USD | 12.33% |
| 2017 | 8.22 Million USD | -6.62% |
| 2016 | 8.8 Million USD | 33.8% |
| 2015 | 6.57 Million USD | -7.75% |
| 2014 | 7.13 Million USD | -20.67% |
| 2013 | 8.99 Million USD | 49.74% |
| 2012 | 6 Million USD | 13.98% |
| 2011 | 5.26 Million USD | 16.83% |
| 2010 | 4.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.2 Million USD | 0.0% |
| 2024 Q1 | 2.2 Million USD | 10.86% |
| 2023 Q4 | 1.98 Million USD | -3.49% |
| 2023 Q2 | 1.98 Million USD | -31.91% |
| 2023 FY | 8.92 Million USD | -18.18% |
| 2023 Q1 | 2.9 Million USD | -11.34% |
| 2023 Q3 | 2.06 Million USD | 4.09% |
| 2022 Q4 | 3.28 Million USD | 18.11% |
| 2022 Q1 | 2.57 Million USD | -39.15% |
| 2022 Q2 | 2.27 Million USD | -11.69% |
| 2022 Q3 | 2.77 Million USD | 22.12% |
| 2022 FY | 10.9 Million USD | -20.37% |
| 2021 Q4 | 4.23 Million USD | 12.52% |
| 2021 FY | 13.69 Million USD | -8.1% |
| 2021 Q1 | 2.31 Million USD | -37.38% |
| 2021 Q2 | 3.38 Million USD | 45.88% |
| 2021 Q3 | 3.76 Million USD | 11.17% |
| 2020 Q3 | 2.69 Million USD | -33.33% |
| 2020 Q4 | 3.7 Million USD | 37.66% |
| 2020 Q1 | 4.47 Million USD | -6.77% |
| 2020 FY | 14.9 Million USD | 6.15% |
| 2020 Q2 | 4.03 Million USD | -9.81% |
| 2019 Q1 | 2.01 Million USD | -28.01% |
| 2019 FY | 14.03 Million USD | 52.04% |
| 2019 Q4 | 4.79 Million USD | 21.71% |
| 2019 Q2 | 3.28 Million USD | 63.33% |
| 2019 Q3 | 3.94 Million USD | 20.1% |
| 2018 Q4 | 2.79 Million USD | 40.65% |
| 2018 FY | 9.23 Million USD | 12.33% |
| 2018 Q2 | 2.23 Million USD | 0.77% |
| 2018 Q3 | 1.98 Million USD | -11.27% |
| 2018 Q1 | 2.22 Million USD | -11.32% |
| 2017 Q2 | 1.94 Million USD | -3.46% |
| 2017 Q3 | 1.75 Million USD | -9.85% |
| 2017 Q1 | 2.01 Million USD | -22.16% |
| 2017 Q4 | 2.5 Million USD | 42.66% |
| 2017 FY | 8.22 Million USD | -6.62% |
| 2016 Q2 | 2.17 Million USD | 27.78% |
| 2016 FY | 8.8 Million USD | 33.8% |
| 2016 Q3 | 2.33 Million USD | 7.13% |
| 2016 Q4 | 2.59 Million USD | 11.05% |
| 2016 Q1 | 1.7 Million USD | -29.38% |
| 2015 Q2 | 1.54 Million USD | 27.09% |
| 2015 Q4 | 2.41 Million USD | 71.11% |
| 2015 Q3 | 1.41 Million USD | -8.62% |
| 2015 FY | 6.57 Million USD | -7.75% |
| 2015 Q1 | 1.21 Million USD | -26.85% |
| 2014 Q2 | 2.16 Million USD | 11.9% |
| 2014 Q3 | 1.37 Million USD | -36.36% |
| 2014 FY | 7.13 Million USD | -20.67% |
| 2014 Q1 | 1.93 Million USD | -43.88% |
| 2014 Q4 | 1.65 Million USD | 20.56% |
| 2013 Q2 | 2.18 Million USD | 26.66% |
| 2013 Q4 | 3.44 Million USD | 122.01% |
| 2013 Q3 | 1.55 Million USD | -28.89% |
| 2013 Q1 | 1.72 Million USD | -17.5% |
| 2013 FY | 8.99 Million USD | 49.74% |
| 2012 Q2 | 1.24 Million USD | -21.33% |
| 2012 Q1 | 1.57 Million USD | 22.02% |
| 2012 Q4 | 2.08 Million USD | 73.79% |
| 2012 Q3 | 1.2 Million USD | -3.25% |
| 2012 FY | 6 Million USD | 13.98% |
| 2011 Q2 | 1.39 Million USD | -14.91% |
| 2011 Q4 | 1.29 Million USD | 10.73% |
| 2011 Q3 | 1.16 Million USD | -16.14% |
| 2011 FY | 5.26 Million USD | 16.83% |
| 2011 Q1 | 1.63 Million USD | 28.59% |
| 2010 Q3 | 1 Million USD | 0.0% |
| 2010 Q4 | 1.27 Million USD | 27.07% |
| 2010 FY | 4.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 72.135% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 3.561% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | 23.272% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 82.812% |
| Azitra, Inc. | 8.3 Million USD | -7.656% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -30.248% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 69.171% |
| CEL-SCI Corporation | 31.47 Million USD | 71.604% |
| iBio, Inc. | 16.85 Million USD | 46.984% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 72.921% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 55.714% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 64.05% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 35.844% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | 30.702% |
| NanoViricides, Inc. | 8.51 Million USD | -4.954% |
| Oragenics, Inc. | 5.45 Million USD | -63.941% |
| BiomX Inc. | 26.81 Million USD | 66.667% |
| BiomX Inc. | 26.81 Million USD | 66.667% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 72.114% |
| Palatin Technologies, Inc. | 34.67 Million USD | 74.22% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 77.552% |